Research output per year
Research output per year
-
Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis
Rüfer, A., Nilius, H., Hermine, O., Niedoszytko, M., Oude Elberink, J. N. G., Bonadonna, P., Shoumariyeh, K., Gulen, T., Hartmann, K., Sabato, V., Angelova-Fischer, I., Baffoe, D., Christen, D., Belloni Fortina, A., Breynaert, C., Brockow, K., von Bubnoff, N., Bumbea, H., van Daele, P. & Doubek, M. & 24 others, , 15 Jan 2025, In: Leukemia. 39, 3, p. 675-683 9 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry
Niedoszytko, M., Gorska, A., Brockow, K., Bonadonna, P., Lange, M., Kluin-Nelemans, H. C., Angelova-Fischer, I., Stefan, A. & et al., Sept 2024, In: Allergy. 79, 9, p. 2470-2481 12 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the ECNM
Rüfer, A., Nilius, H., Hermine, O., Niedoszytko, M., Elberink, H. O., Angelova-Fischer, I., Stefan, A. & et al., Sept 2024, ResearchSquare, 34 p. (Resarch Square).Research output: Working paper and reports › Preprint
-
Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM.
Lübke, J., Schmid, A., Christen, D., Elberink, H. O., Lange, M., Stefan, A., Angelova-Fischer, I. & et al., 11 Jun 2024, In: Blood Advances. 8, 11, p. 2890-2900 11 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Mast Cell Leukemia: Clinical and Molecular Features and Survival Outcomes of Patients in the ECNM Registry
Kennedy, V., Perkins, C., Reiter, A., Jawhar, M., Lübke, J., Kluin-Nelemans, H. C., Shomali, W., Langford, C., Angelova-Fischer, I., Solomianyi, O. & et al., 09 May 2023, In: Blood Advances. 7, 9, p. 1713-1724 12 p.Research output: Contribution to journal › Article › peer-review
Open Access
-
ABCSG61 Teodor
Stegemann, M. (Researcher), Kausche, L. E. (Researcher), Lichtenauer, N. (Researcher), Popp, H. D. (Researcher), Schwarz, H. K. (Researcher), Kühr, T. (Researcher), Schneeweiß, B. (Researcher), Ghanem, R. (Researcher), Schmitt, C. (Researcher), Preuß, C. (Researcher), Piringer, G. (Researcher), Stefan, A. (Researcher) & Kovacsova, J. (Researcher)
03.03.2026 → 02.09.2028
Project: Clinical studies › Clinical Study (Industry project)
-
Camelot-2
Popp, H. (Researcher), Lichtenauer, N. (Researcher), Kausche, L. E. (Researcher), Stegemann, M. (Researcher), Ghanem, R. (Researcher), Schneeweiß, B. (Researcher), Schmitt, C. (Researcher), Schwarz, H. K. (Researcher), Piringer, G. (Researcher), Kovacsova, J. (Researcher), Stefan, A. (Researcher) & Kühr, T. (Researcher)
01.12.2025 → 31.12.2029
Project: Clinical studies › Clinical Study (Industry project)
-
KRT-232-115
Lichtenauer, N. (Researcher), Stegemann, M. (Researcher), Stefan, A. (Researcher), Kausche, L. E. (Researcher), Piringer, G. (Researcher), Ghanem, R. (Researcher), Schmitt, C. (Researcher), Kovacsova, J. (Researcher), Popp, H. (Researcher), Schwarz, H. K. (Researcher), Schneeweiß, B. (Researcher) & Kühr, T. (Researcher)
01.09.2025 → 28.02.2029
Project: Clinical studies › Clinical Study (Industry project)
-
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo- Controlled, Parallel-Arm Study Followed by an Open-Label Arm to Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia (ARGX-113-2402)
Schmitt, C. (PI), Krivic, D. (Researcher), Lichtenauer, N. (Researcher), Kühr, T. (Researcher), Schneeweiß, B. (Researcher), Piringer, G. (Researcher), Popp, H. D. (Researcher), Krenosz, K. J. (Researcher), Ghanem, R. (Researcher), Stefan, A. (Researcher), Schwarz, H. K. (Researcher), Kovacsova, J. (Researcher), Kausche, L. E. (Researcher), Stegemann, M. (Researcher), Klein, K. (Researcher) & Trathnigg, N. (Researcher)
04.06.2025 → 31.05.2029
Project: Clinical studies › Clinical Study (Industry project)
-
Phase III randomized, open-label, international, multicenter study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti- CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma (MorningLyte)
Schmitt, C. (PI), Krivic, D. (Researcher), Lichtenauer, N. (Researcher), Kühr, T. (Researcher), Schneeweiß, B. (Researcher), Piringer, G. (Researcher), Popp, H. D. (Researcher), Krenosz, K. J. (Researcher), Ghanem, R. (Researcher), Stefan, A. (Researcher), Schwarz, H. K. (Researcher), Kovacsova, J. (Researcher), Kausche, L. E. (Researcher), Stegemann, M. (Researcher), Klein, K. (Researcher) & Trathnigg, N. (Researcher)
02.06.2025 → 31.05.2029
Project: Clinical studies › Clinical Study (Industry project)
-
Systemische Mastozytose
Stefan, A. (Speaker)
20 Nov 2025Activity: Talk or presentation › Invited talk › science-to-science
-
Myeloisch: Kurz und prägnant: Klinisch relevante Veränderungen 2025
Popp, H. (Speaker), Schmitt, C. (Contributor), Stegemann, M. (Speaker), Stefan, A. (Speaker), Rumpold, H. (Contributor), Heibl, S. (Contributor), Clausen, J. (Speaker), Rotter, N. (Speaker), Strassl, I. (Speaker) & Heine, A. (Speaker)
11 Nov 2025Activity: Talk or presentation › Invited talk › science-to-science
-
Lymphom: Unmet clinical need
Stegemann, M. (Speaker), Schmitt, C. (Contributor), Popp, H. (Speaker), Stefan, A. (Speaker), Rumpold, H. (Contributor), Clausen, J. (Speaker), Rotter, N. (Speaker), Strassl, I. (Speaker), Heine, A. (Speaker) & Heibl, S. (Speaker)
11 Nov 2025Activity: Talk or presentation › Invited talk › science-to-science
-
Myeloproliferative Neoplasie: Kurz & Prägnant
Stefan, A. (Speaker)
11 Nov 2025Activity: Talk or presentation › Invited talk › science-to-science
-
Fallpräsentation
Stefan, A. (Speaker)
14 Oct 2025Activity: Talk or presentation › Other talk or presentation › science-to-science